Bleomycin
Also known as: BLE, Blenoxane, Bleo, Bleomycin A2, Bleomycin B2, Bleomycin sulfate, BLM
Source Bleomycin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Bleomycin is a glycopeptide antibiotic that is also used as an anticancer agent. It is administered by injection (intravenous, intramuscular, subcutaneous, or intrapleural) and is a component of combination chemotherapy regimens such as BEP for ovarian sex‑cord stromal tumors and ABVD for Hodgkin lymphoma. Clinical trials have evaluated these regimens for disease control, while limited topical studies have explored bleomycin for oral lesions.
Mechanism of Action
Bleomycin binds to DNA and, in the presence of Fe(II) and molecular oxygen, generates free radicals that cause single- and double-strand DNA breaks, leading to cell cycle arrest (G2/M phase) and apoptosis in rapidly dividing cells.
What the Research Shows
A phase II non‑inferiority trial in ovarian sex‑cord stromal tumors compared paclitaxel‑carboplatin with a BEP regimen that includes bleomycin; the BEP arm showed a median progression‑free survival of 19.7 months but incurred grade 3 or higher adverse events in 90% of patients. In a large randomized Hodgkin lymphoma study, early PET‑guided adaptation showed that patients whose disease was PET‑positive after two cycles of ABVD (which contains bleomycin) benefited from intensification to a BEACOPP‑esc regimen, also containing bleomycin, achieving a 5‑year PFS of 90.6% versus 77.4% with standard therapy. A Cochrane review identified a single small trial of topical bleomycin for oral leukoplakia (20 participants) that showed no clear reduction in cancer risk, with very low‑quality evidence. No robust data were found for topical bleomycin in cutaneous warts.
Reported Benefits
When used intravenously as part of BEP, bleomycin contributes to disease control in ovarian stromal tumors, achieving a median PFS of roughly 20 months. In Hodgkin lymphoma, inclusion of bleomycin in ABVD and subsequent BEACOPP‑esc intensification improves 5‑year progression‑free survival for PET‑positive patients (up to 90.6%). Topical bleomycin has been studied in a very small oral leukoplakia trial, but no benefit was demonstrated.
Limitations of the Evidence
Evidence for bleomycin’s efficacy is confined to combination regimens; no trials isolate bleomycin alone. The ovarian tumor study was stopped early for futility of the comparator arm, limiting definitive conclusions. Toxicity was high in the BEP arm (90% grade 3+ events). Topical use data are scarce, derived from a single small study with wide confidence intervals, and overall evidence quality is low. No randomized data support bleomycin for warts or other dermatologic conditions.
Safety Considerations
In the BEP regimen, grade 3 or higher adverse events occurred in 90% of patients, reflecting considerable toxicity when bleomycin is combined with etoposide and cisplatin. The Hodgkin lymphoma trial reported overall treatment‑related adverse events but did not isolate bleomycin‑specific effects. Topical bleomycin studies reported side‑effects of varying severity, though details were limited. Clinicians should monitor patients closely for systemic toxicity when bleomycin is administered intravenously.
How It Is Administered
Bleomycin is supplied for injection and may be given intravenously, intramuscularly, subcutaneously, or intrapleurally, typically as part of multi‑drug chemotherapy protocols. Formulations are provided as a sulfate salt for sterile solution use.
Routes of Administration
Goals & Uses
- Testicular germ cell tumor treatmentOncologyHigh
- Testicular cancerOncologyHigh
- Ovarian germ cell tumor treatmentOncologyModerate
- Hodgkin lymphoma treatmentOncologyHigh
- Cutaneous warts (off‑label)DermatologyLow
- Squamous cell carcinoma of head & neckOncologyModerate
- Squamous cell carcinoma treatmentOncologyModerate
- Malignant pleural effusionOncologyModerate
- Malignant pleural effusion sclerotherapyPalliative OncologyModerate
- Hodgkin lymphomaOncologyHigh
- Non-Hodgkin lymphoma treatmentOncologyModerate
Contraindications
- Severe pulmonary diseaseRespiratoryHigh
- Severe renal impairment (creatinine clearance <30 mL/min)RenalModerate
- Prior severe bleomycin pulmonary toxicityDrug Toxicity HistoryHigh
- Severe renal impairmentOrganModerateKidney function concerns
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Hypersensitivity to bleomycinAllergy/immunologyHigh
- Cumulative dose >400 unitsOncology/safetyHigh
- Pre‑existing pulmonary fibrosisRespiratoryHigh
- High‑concentration oxygen therapy (>30% FiO2)RespiratoryHigh
Adverse Effects
- Skin rash / hyperpigmentationDermatologicCommon
- AlopeciaDermatologicUncommonHair loss
- Cutaneous toxicity (skin thickening, hyperpigmentation, alopecia)DermatologicCommon
- Pulmonary fibrosis/pneumonitisRespiratoryUncommon
- Nausea/vomitingGastrointestinalCommon
- Fever and chillsConstitutionalCommon
- Nausea and vomitingGastrointestinalCommon
- MucositisGastrointestinal / MucosalUncommon
- MyelosuppressionHematologicUncommon
- Anaphylactoid/idiosyncratic reactionsImmunologicUncommon
- Pulmonary fibrosisPulmonaryCommon
Drug Interactions
- Radiation therapyHigh
- AmiodaroneModerate
- Supplemental oxygen (high FiO2)High
- DigoxinLow
- PhenytoinModerate
- G‑CSF (filgrastim)Moderate
- CisplatinModerate
- Granulocyte colony-stimulating factors (G-CSF)Moderate
- High inspired oxygenHigh
Population Constraints
- SmokersLifestyleRelative
- Patients with chronic lung diseaseRespiratoryRelative
- Renal impairmentOrgan ImpairmentRelative
- Elderly patients (≥70 years)AgeRelative
- Patients undergoing general anesthesiaPerioperativeRelative
- Children (<12 y)PediatricRelative
- Elderly (>70 y)GeriatricRelative
- Patients with renal impairmentOrgan ImpairmentRelative
- Pregnant womenReproductiveAbsolute
Regulatory Status
- European UnionApprovedApproved: Hodgkin lymphoma, Testicular cancer, Squamous cell carcinomaEMA approval; same safety concerns
- United StatesApprovedApproved: Hodgkin lymphoma, Testicular cancer, Squamous cell carcinoma of head and neck, Malignant pleural effusionFDA‑approved; boxed warning for pulmonary toxicity
- United KingdomApprovedApproved: Hodgkin lymphoma, Testicular cancer, Squamous cell carcinomaMHRA approval; used under specialist supervision
Approved for Hodgkin lymphoma, testicular cancer, and squamous cell carcinoma; contraindicated in patients with pre‑existing pulmonary fibrosis and during high‑concentration oxygen therapy due to risk of severe lung injury.
Evidence & Sources
- Journal ArticleModerateBrown J, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateAndré MPE, et al.2017-01-01T00:00:00.000000Z
- Journal ArticleHighLodi G, et al.2016-01-01T00:00:00.000000Z
- Journal ArticleHighKwok CS, et al.2012-01-01T00:00:00.000000Z
- Journal ArticleHighGarcía-Oreja S, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleHighMoeller A, et al.2008-01-01T00:00:00.000000Z
Frequently Asked Questions
What types of cancer are treated with bleomycin‑containing regimens?
Bleomycin is incorporated into BEP for ovarian sex‑cord stromal tumors and into ABVD (and BEACOPP‑esc) for Hodgkin lymphoma, where it contributes to disease control as part of combination chemotherapy.
Is bleomycin effective when applied topically for oral lesions or warts?
A small trial of topical bleomycin for oral leukoplakia showed no clear reduction in cancer risk, and evidence is judged very low quality. No robust data support its use for cutaneous warts.
What are the main safety concerns with intravenous bleomyulin?
In combination regimens, high‑grade adverse events are common (90% grade 3+ in a BEP trial). Systemic toxicity can be significant, requiring careful monitoring during treatment.
How is bleomycin administered in clinical practice?
Bleomycin is given by injection—intravenous, intramuscular, subcutaneous, or intrapleural—usually as part of multi‑agent chemotherapy protocols.
Why was the ovarian tumor trial stopped early?
The study was halted for futility because the paclitaxel‑carboplatin arm failed to meet the pre‑specified non‑inferiority margin compared with the BEP regimen, limiting further accrual.
What is Bleomycin?
Bleomycin is a glycopeptide antibiotic that is also used as an anticancer agent. It is administered by injection (intravenous, intramuscular, subcutaneous, or intrapleural) and is a component of combination chemotherapy regimens such as BEP for ovarian sex‑cord stromal tumors and ABVD for Hodgkin lymphoma. Clinical trials have evaluated these regimens for disease control, while limited topical studies have explored bleomycin for oral lesions.
What is Bleomycin used for?
Bleomycin is educationally associated with: Testicular germ cell tumor treatment, Testicular cancer, Ovarian germ cell tumor treatment, Hodgkin lymphoma treatment, Cutaneous warts (off‑label), Squamous cell carcinoma of head & neck, Squamous cell carcinoma treatment, Malignant pleural effusion, Malignant pleural effusion sclerotherapy, Hodgkin lymphoma, Non-Hodgkin lymphoma treatment. Educational only — not medical advice.
How is Bleomycin administered?
Recorded routes of administration: Intralesional, Intramuscular, Intrapleural, Intravenous, Subcutaneous.
What are the potential side effects of Bleomycin?
Reported adverse effects include: Skin rash / hyperpigmentation, Alopecia, Cutaneous toxicity (skin thickening, hyperpigmentation, alopecia), Pulmonary fibrosis/pneumonitis, Nausea/vomiting, Fever and chills, Nausea and vomiting, Mucositis, Myelosuppression, Anaphylactoid/idiosyncratic reactions, Pulmonary fibrosis. This list is not exhaustive — consult a qualified clinician.
Who should avoid Bleomycin?
Recorded contraindications: Severe pulmonary disease, Severe renal impairment (creatinine clearance <30 mL/min), Prior severe bleomycin pulmonary toxicity, Severe renal impairment, Pregnancy, Hypersensitivity to bleomycin, Cumulative dose >400 units, Pre‑existing pulmonary fibrosis, High‑concentration oxygen therapy (>30% FiO2). Consult a qualified clinician before use.